NVCR logo

NOVOCURE LTD

NVCRNASDAQ
πŸ† #2160 by market capUS Equity
β€”β€”
Quote unavailable
πŸ””
Track NVCR
Get earnings, price moves & breaking news on Telegram
Track
24hβ€”
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$1.25B
Small Cap
πŸ“ˆRevenue Growth (YoY)
12.9%
Healthy
πŸ“ŠGross Margin
77.0%
High
πŸ’΅FCF Margin
2.3%
Thin
βš–οΈP/S Ratio
1.7x
Cheap
Otter Score
68
Fair
No chart data available for NVCR.

Trading Snapshot

Day Range
β€”
52-Week Range
$9.82 – $21.45
Volume (shares)
β€”
Avg Volume (shares)
β€”
Shares Outstanding
116.9M
Next Earnings
β€”

Fundamentals Snapshot

Annual Revenue
$655M
Last Q Revenue
$193M
P/E Ratio
β€”
P/S Ratio
1.7x
EPS (TTM)
$-1.07
Dividend Yield
β€”
Dilution (1yr)
+3.4%
NVCR logo

NOVOCURE LTD

NVCR
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$655Mβ–² +8.3% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
74.5%β–Ό βˆ’3.6% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$154Mβ–Ό βˆ’9.8% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$76Mβ–² +9.3% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
111.5Mβ–² +3.4% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$187Mβ–² +$333M YoY
StockOtter Β· stockotter.space

About NOVOCURE LTD

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Fair
68/100
Analyst data unavailable.

Latest News & Updates

News unavailable.